MedWatch

A part of Watch Media

CEO of Pila Pharma increases share holding to over a third

Dorte X. Gram, the founder and CEO of Danish-Swedish Pila Pharma has purchased shares in the diabetes firm, giving her 31-percent ownership. The price per share was less than in summer when the firm went public, and Gram says that at the current price, there is "no better investment than this one."

Photo: Jenny Leyman / Pila Pharma / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

On Monday this week, CEO Dorte X. Gram's belief in Pila Pharma's future manifested itself strongly, as she purchased a considerable portion of shares increasing her ownership to almost a third, the firm reported in a press release on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Foto: Tyrone Siu/Reuters/Ritzau Scanpix

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

  1. Board chair at Coloplast and Lundbeck warns against large pay rises
  2. Ellab slapped with customs fine over US imports
  3. China approves Y-mabs drug
  4. CEO gets "taste of own medicine" by participating in vaccine trial
  5. FDA approves Covid-19 jabs as boosters for infants
  6. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  7. FDA approves new sensor for insulin pens
  8. Full house for Ambu – all products live up to new EU requirements
  9. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  10. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  11. New majority owner makes several board appointments at hearing firm
  12. FDA awards Pfizer's RSV vaccine candidate priority review status
  13. More countries back EU Commission investigation into potential Oticon sale
  14. Nobel Prize winner: "Good research is driven by curiosity"
  15. Forward Pharma's last hope in protracted Biogen battle extinguished

See all

Job

See all jobs

See all jobs